How Does BNP Work? Mechanism of Action, Per the Research

B-type natriuretic peptide (BNP) is one of the best-characterised cardiac hormones in the published literature. This page summarises what pharmacology reviews and experimental papers describe about where BNP comes from, which receptors it binds, what second messenger it uses, and how it is cleared. This page is for educational purposes only and is not medical advice; consult a licensed physician for any clinical question. No dosing, protocol or administration information appears here.

Where BNP Comes From: Gene, Precursor and Processing

Reviews of natriuretic peptide biochemistry described BNP as the product of the NPPB gene, which is transcribed into preproBNP and processed to proBNP, a 108-amino-acid precursor; researchers reported that proBNP is cleaved into the biologically active 32-amino-acid BNP and the inactive 76-amino-acid N-terminal fragment NT-proBNP (PMID 14987573). A dedicated review of NT-proBNP described the same precursor chemistry and emphasised that only the C-terminal BNP fragment carries receptor-mediated activity, while NT-proBNP circulates as a marker without known receptor signalling (PMID 15948107).

A review describing the heart as an endocrine gland reported that the natriuretic peptide family comprises atrial natriuretic peptide (ANP), BNP and C-type natriuretic peptide (CNP), each with a conserved 17-amino-acid ring closed by a disulphide bridge that is required for receptor binding (PMID 34871602). Reviews of natriuretic peptide biology reported that ANP is stored mainly in atrial granules and released rapidly, whereas BNP is produced largely by ventricular myocytes with transcription induced by wall stress, so BNP output reflects ventricular loading over time rather than a preformed store (PMID 18243856).

The same body of work reported that glycosylation of proBNP within the cleavage region influences how efficiently the precursor is processed, which means circulating immunoreactivity can include unprocessed proBNP alongside mature BNP (PMID 15948107). A review of assay interpretation in the neprilysin-inhibitor era described this heterogeneity of circulating BNP-related forms as a reason that BNP and NT-proBNP measurements behave differently from one another (PMID 32951154).

The Established Mechanism: NPR-A and Cyclic GMP

The core, well-replicated mechanism described in pharmacology reviews is receptor-coupled guanylyl cyclase signalling. A handbook review of natriuretic peptide structures and receptors reported three receptors — NPR-A (GC-A), NPR-B (GC-B) and NPR-C — and described NPR-A as the principal receptor for ANP and BNP, with NPR-B preferentially activated by CNP and NPR-C functioning primarily as a clearance receptor (PMID 19089336).

Reviews described NPR-A as a single-transmembrane protein with an extracellular ligand-binding domain, a kinase-homology domain and an intracellular guanylyl cyclase domain; researchers reported that peptide binding triggers conformational change and ATP-dependent activation of the cyclase, converting GTP to cyclic GMP (PMID 19089336). A basic-science review of the natriuretic peptides reported that the resulting rise in intracellular cGMP activates cGMP-dependent protein kinase (protein kinase G), cGMP-gated ion channels and cGMP-regulated phosphodiesterases, which together constitute the downstream effector arm of the pathway (PMID 14963664).

Signalling Steps as Described

1. BNP is secreted from ventricular myocytes in response to myocardial stretch and wall stress (PMID 18243856).
2. BNP binds the extracellular domain of NPR-A on vascular smooth muscle, endothelium, kidney and adrenal tissue (PMID 19089336).
3. The intracellular guanylyl cyclase domain generates cGMP (PMID 19089336).
4. cGMP activates protein kinase G and related effectors, producing smooth muscle relaxation and altered renal tubular sodium handling (PMID 14963664).
5. Signalling is terminated by NPR-C-mediated internalisation and by enzymatic degradation (PMID 19089336).

Downstream Physiology Described in the Literature

Reviews of natriuretic peptide physiology reported that NPR-A activation in the kidney increases glomerular filtration and reduces sodium reabsorption in the collecting duct, producing natriuresis and diuresis, while vascular cGMP signalling relaxes smooth muscle and lowers vascular tone (PMID 14963664). The biochemistry review of (NT-pro)BNP described the system as a counter-regulatory axis to volume and pressure overload, with BNP release rising as ventricular filling pressures rise (PMID 14987573).

Researchers reported that natriuretic peptide signalling opposes the renin–angiotensin–aldosterone system by suppressing renin release and adrenal aldosterone secretion, and also restrains sympathetic outflow (PMID 18243856). A review of cardiovascular pleiotropic effects described additional actions attributed to the axis, including anti-fibrotic and anti-hypertrophic signalling in cardiac tissue, effects on endothelial permeability and modulation of inflammatory pathways (PMID 31398927).

How BNP Is Cleared: NPR-C and Neprilysin

Clearance is as much a part of the mechanism as receptor activation. Reviews reported two principal routes: binding to NPR-C followed by receptor-mediated internalisation and lysosomal degradation, and enzymatic cleavage by neprilysin, a zinc-dependent membrane metallopeptidase (PMID 19089336). A review of angiotensin receptor–neprilysin inhibitors and the natriuretic peptide axis described neprilysin as degrading multiple vasoactive substrates, so that inhibiting the enzyme raises circulating natriuretic peptide availability while also affecting other peptide pools (PMID 32394149).

This clearance biology explains a measurement asymmetry that researchers described in detail: because BNP is a neprilysin substrate and NT-proBNP is not, neprilysin inhibition can raise measured BNP while NT-proBNP reflects production more than degradation, which the review framed as central to interpreting the two assays differently (PMID 32951154). The NT-proBNP mechanism review similarly reported that the two fragments differ in half-life and elimination pathways, with renal handling contributing to NT-proBNP levels (PMID 15948107).

Established Mechanism Versus Proposed Mechanism

The literature distinguishes clearly between mechanism that is structurally and biochemically established and mechanism that remains hypothesis-generating.

Established in published pharmacology

• NPR-A is a particulate guanylyl cyclase and the principal BNP receptor (PMID 19089336).
• cGMP and protein kinase G are the second-messenger effectors (PMID 14963664).
• Ventricular wall stress drives NPPB transcription and BNP release (PMID 18243856).
• Neprilysin and NPR-C clear circulating peptide (PMID 32394149).

Proposed or still under investigation

• Metabolic actions. A review of natriuretic peptides in cardiometabolic disease reported proposed roles in adipose tissue lipolysis, browning of fat and insulin sensitivity, framed as an emerging rather than settled area (PMID 32537542).
• Pleiotropic tissue effects. The pleiotropy review described anti-inflammatory, anti-remodelling and endothelial actions as biologically plausible extensions of cGMP signalling that require further confirmation (PMID 31398927).
• CNP/NPR-B crosstalk. A 2025 perspective reported that CNP signalling through NPR-B is being examined for cardiometabolic relevance distinct from the ANP/BNP–NPR-A arm (PMID 41378499).
• Protection of BNP from local degradation. A 2023 experimental study in cardiac tissue reported that inhibiting fibroblast activation protein (FAP) stabilised BNP and promoted cardiac repair, identifying FAP as an additional protease acting on the peptide (PMID 36756875). That work was preclinical and does not describe human clinical outcomes.

Preclinical and Mechanistic Context

Much of the receptor-level detail in this field comes from in vitro receptor pharmacology and animal models rather than from human dosing studies, and reviews presented it as such (PMID 19089336). The FAP study described above was conducted in a preclinical cardiac repair model and reported peptide stabilisation as the proposed mechanism linking enzyme inhibition to tissue effect (PMID 36756875). Readers comparing mechanism papers will find that cell and animal findings are frequently extrapolated to human physiology in secondary literature; the primary descriptions keep the distinction.

Why Mechanism Matters for Interpreting BNP as a Marker

Because BNP is both a signalling hormone and a routinely measured analyte, mechanism and measurement are intertwined. Researchers reported that circulating concentrations reflect the balance of transcription, precursor processing, receptor-mediated clearance and enzymatic degradation, so a change in any of those steps alters the measured value independently of the others (PMID 14987573). The neprilysin-era review made the point explicitly, reporting that pharmacological interference with clearance changes BNP and NT-proBNP in different directions and that interpretation must account for which analyte was measured (PMID 32951154).

The endocrine review framed the whole system as the heart acting as an endocrine organ, with secretion tuned to haemodynamic load and effects distributed across kidney, vasculature and adrenal tissue (PMID 34871602). That framing is the most useful single summary of how BNP works: a stretch-sensing hormone that signals through a guanylyl cyclase receptor to lower volume and pressure.

For background on BNP's identity, nomenclature and research context, see the overview at /learn/bnp/. Nothing on this page describes administration, dosing or use in people; it summarises published mechanism only, and clinical questions belong with a licensed physician.

References

• Essential biochemistry and physiology of (NT-pro)BNP (European Journal of Heart Failure, 2004)
• NT-ProBNP: the mechanism behind the marker (Journal of Cardiac Failure, 2005)
• Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications (Handbook of Experimental Pharmacology, 2009)
• Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP (Circulation Research, 2023)
• The natriuretic peptides (Basic Research in Cardiology, 2004)
• Cardiovascular Pleiotropic Effects of Natriuretic Peptides (International Journal of Molecular Sciences, 2019)
• Perspectives on C-Type Natriuretic Peptide in Cardiometabolic Disease (Journal of the American Heart Association, 2025)
• BNP and NT-proBNP Interpretation in the Neprilysin Inhibitor Era (Current Cardiology Reports, 2020)
• Biology of the natriuretic peptides (The American Journal of Cardiology, 2008)
• The heart, an endocrine gland: Natriuretic peptides (Annales d'Endocrinologie, 2022)
• The Importance of Natriuretic Peptides in Cardiometabolic Diseases (Journal of the Endocrine Society, 2020)
• Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis (Current Heart Failure Reports, 2020)